March 5, 2021
Amgen signs agreement to acquire Five Prime Therapeutics for $1.9bn
Clinical-stage biotechnology company Amgen has signed an agreement to acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of around $1.9bn.